Search results
Results: 89
Number of items: 89
-
Boekel, L., Tas, S. W., Takkenberg, R. B., Bemelman, F. J., de Wit, J., Verstegen, N. J. M., van Ham, S. M., & T2B! immunity against SARS-CoV-2 study group (2022). Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. The Lancet. Rheumatology, 4(6), e417-e429. https://doi.org/10.1016/S2665-9913(22)00102-3
-
Wieske, L., Tas, S. W., Takkenberg, R. B., Verstegen, N. J. M., Zwinderman, K. A. H., van Ham, S. M., & T2B! immunity against SARS-CoV-2 study group (2022). Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. The Lancet. Rheumatology, 4(5), e338-e350. https://doi.org/10.1016/S2665-9913(22)00034-0
-
van Kempen, Z. L. E., Wieske, L., Stalman, E. W., Kummer, L. Y. L., van Dam, P. J., Volkers, A. G., Boekel, L., Toorop, A. A., Strijbis, E. M. M., Tas, S. W., Wolbink, G. J., Löwenberg, M., van Sandt, C., ten Brinke, A., Verstegen, N. J. M., Steenhuis, M., Kuijpers, T. W., van Ham, S. M., Rispens, T., ... T2B! immunity against SARS-CoV-2 study group (2022). Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate? Multiple sclerosis and related disorders, 57, Article 103416. https://doi.org/10.1016/j.msard.2021.103416 -
Palomares Cabeza, V., Kummer, L. Y. L., Wieske, L., Hagen, R. R., Duurland, M., Konijn, V. A. L., van Dam, K. P. J., Stalman, E. W., van de Sandt, C. E., Boekel, L., Verstegen, N. J. M., Steenhuis, M., Rispens, T., Tas, S. W., Wolbink, G., Killestein, J., Kuijpers, T. W., van Ham, S. M., Eftimov, F., ... Target-to-B! (T2B!) SARS-CoV-2 study group (2022). Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod. Neurology® Neuroimmunology & Neuroinflammation, 9(4), Article e1178. https://doi.org/10.1212/NXI.0000000000001178
-
Bos, A. V., van Gool, M. M. J., Breedveld, A. C., van der Mast, R., Marsman, C., Bouma, G., van de Wiel, M. A., van Ham, S. M., Mebius, R. E., & van Egmond, M. (2022). Fcα Receptor-1-Activated Monocytes Promote B Lymphocyte Migration and IgA Isotype Switching. International Journal of Molecular Sciences, 23(19), Article 11132. https://doi.org/10.3390/ijms231911132
-
Koers, J., Pollastro, S., Tol, S., Pico-Knijnenburg, I., Derksen, N. I. L., van Schouwenburg, P. A., van der Burg, M., van Ham, S. M., & Rispens, T. (2022). CD45RB Glycosylation and Ig Isotype Define Maturation of Functionally Distinct B Cell Subsets in Human Peripheral Blood. Frontiers in Immunology, 13, Article 891316. https://doi.org/10.3389/fimmu.2022.891316
-
Verstegen, N. J. M., Hagen, R. R., van den Dijssel, J., Kuijper, L. H., Kreher, C., Ashhurst, T., Kummer, L. Y. L., Steenhuis, M., Duurland, M., de Jongh, R., de Jong, N., van der Schoot, C. E., Bos, A. V., Mul, E., Kedzierska, K., van Dam, K. P. J., Stalman, E. W., Boekel, L., Wolbink, G., ... T2B! immunity against SARS-CoV-2 study group (2022). Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273. eLife, 11, Article e77969. https://doi.org/10.7554/eLife.77969
-
Marsman, C., Verstegen, N. J. M., Streutker, M., Jorritsma, T., Boon, L., Ten Brinke, A., & van Ham, S. M. (2022). Termination of CD40L co-stimulation promotes human B cell differentiation into antibody-secreting cells. European journal of immunology, 52(10), 1662-1675. https://doi.org/10.1002/eji.202249972
-
Marsman, C., Verhoeven, D., Koers, J., Rispens, T., ten Brinke, A., van Ham, S. M., Kuijpers, T. W., & T2B Consortium (2022). Optimized Protocols for In-Vitro T-Cell-Dependent and T-Cell-Independent Activation for B-Cell Differentiation Studies Using Limited Cells. Frontiers in Immunology, 13, Article 815449. https://doi.org/10.3389/fimmu.2022.815449
Page 5 of 9